These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 11704861)

  • 21. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.
    Chernicky CL; Yi L; Tan H; Gan SU; Ilan J
    Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer.
    Surmacz E; Bartucci M
    J Exp Clin Cancer Res; 2004 Sep; 23(3):385-94. PubMed ID: 15595626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities.
    Tan M; Yao J; Yu D
    Cancer Res; 1997 Mar; 57(6):1199-205. PubMed ID: 9067293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications.
    Chang Q; Li Y; White MF; Fletcher JA; Xiao S
    Cancer Res; 2002 Nov; 62(21):6035-8. PubMed ID: 12414625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
    Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
    Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
    Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor.
    Arteaga CL; Osborne CK
    Cancer Res; 1989 Nov; 49(22):6237-41. PubMed ID: 2553250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.
    Byron SA; Horwitz KB; Richer JK; Lange CA; Zhang X; Yee D
    Br J Cancer; 2006 Nov; 95(9):1220-8. PubMed ID: 17043687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
    Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNAi-mediated silencing of insulin receptor substrate 1 (IRS-1) enhances tamoxifen-induced cell death in MCF-7 breast cancer cells.
    Cesarone G; Garofalo C; Abrams MT; Igoucheva O; Alexeev V; Yoon K; Surmacz E; Wickstrom E
    J Cell Biochem; 2006 May; 98(2):440-50. PubMed ID: 16440325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.
    Lee WJ; Chen WK; Wang CJ; Lin WL; Tseng TH
    Toxicol Appl Pharmacol; 2008 Jan; 226(2):178-91. PubMed ID: 17961621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors.
    Denley A; Carroll JM; Brierley GV; Cosgrove L; Wallace J; Forbes B; Roberts CT
    Mol Cell Biol; 2007 May; 27(10):3569-77. PubMed ID: 17325037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased IRS-2 content and activation of IGF-I pathway contribute to enhance beta-cell mass in fetuses from undernourished pregnant rats.
    Fernández E; Martín MA; Fajardo S; Escrivá F; Alvarez C
    Am J Physiol Endocrinol Metab; 2007 Jan; 292(1):E187-95. PubMed ID: 16912057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line.
    Sepp-Lorenzino L; Rosen N; Lebwohl DE
    Cell Growth Differ; 1994 Oct; 5(10):1077-83. PubMed ID: 7848909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.
    Rocha RL; Hilsenbeck SG; Jackson JG; VanDenBerg CL; Weng Cn; Lee AV; Yee D
    Clin Cancer Res; 1997 Jan; 3(1):103-9. PubMed ID: 9815544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors.
    Plymate SR; Tennant MK; Culp SH; Woodke L; Marcelli M; Colman I; Nelson PS; Carroll JM; Roberts CT; Ware JL
    Prostate; 2004 Nov; 61(3):276-90. PubMed ID: 15368471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
    Zhang H; Pelzer AM; Kiang DT; Yee D
    Cancer Res; 2007 Jan; 67(1):391-7. PubMed ID: 17210722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance.
    Fernández Y; España L; Mañas S; Fabra A; Sierra A
    Cell Death Differ; 2000 Apr; 7(4):350-9. PubMed ID: 10773819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proinflammatory cytokines block growth of breast cancer cells by impairing signals from a growth factor receptor.
    Shen WH; Zhou JH; Broussard SR; Freund GG; Dantzer R; Kelley KW
    Cancer Res; 2002 Aug; 62(16):4746-56. PubMed ID: 12183434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.